The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Investigative Models for Determining Hormone Therapy‐Induced Outcomes in Brain: Evidence in Support of a Healthy Cell Bias of Estrogen Action
Abstract
A bstract: The profound disparities between the largely positive basic science findings of gonadal steroid action in brain and the adverse outcomes of recent hormone therapy clinical trials in women who are either aged postmenopausal or postmenopausal with Alzheimer's disease have led to an intense reassessment of gonadal hormone action and the model systems used in basic and clinical science. The power of model systems is their predictive validity for a target population—in this case, menopausal women considering the health benefits and risks of hormone therapy. Analysis of the model systems used across the basic to clinical research continuum separate into two broad classes: those that use prevention interventions in healthy organisms and those that use hormone interventions in organisms with compromised neurological function. Basic science analyses that led to elucidation of the neurotrophic and neuroprotective effects of estrogen and the underlying mechanisms of action typically used a prevention‐based experimental paradigm. This paradigm relies on healthy neurons/brains/animals/humans as the starting foundation followed by exposure to estrogen/hormone followed by exposure to neurodegenerative insult. The prevention paradigm in basic science analyses parallels the analyses of Sherwin and colleagues (Psychoneuroendocrinology13: 345‐357, 1988), who investigated the cognitive impact of estrogen therapy in women with surgical‐ or pharmacological‐induced menopause. Observational retrospective and prospective studies are also consistent with the healthy cell bias of estrogen action and a prevention paradigm of estrogen or hormone therapy intervention. For the most part, the epidemiological observational data indicate reduction in the risk of Alzheimer's disease in women who began estrogen or hormone therapy at the time of the menopause. In contrast, studies that fall within the second class, hormone intervention in organisms with compromised neurological function—that is, a treatment paradigm—exhibit a mixed profile. In a randomized double‐blind clinical trial of estrogen therapy in a cohort of women aged 72 or more years and diagnosed with Alzheimer's disease, estrogen therapy resulted in a modest benefit in the short term (2 months) and adverse progression of disease in the long term (12 months). In the Women's Health Initiative Memory Study (WHIMS) cohort of women 65 or more years of age, with no indicators of neurological disease but with variable health status, estrogen and hormone therapy for 5 years increased the risk of developing Alzheimer's disease. These data would suggest that as the continuum of neurological health progresses from healthy to unhealthy, so too do the benefits of estrogen or hormone therapy. If neurons are healthy at the time of estrogen exposure, their response to estrogen is beneficial for both neurological function and survival. In contrast, if neurological health is compromised, estrogen exposure over time exacerbates neurological demise. Based on these and other data, a hypothesis of a healthy cell bias of gonadal hormone action is put forth. The healthy cell bias of estrogen action hypothesis provides a lens through which to assess the disparities in outcomes across the domains of scientific inquiry and to access future applications of estrogen and hormone therapeutic interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estrogen Actions Throughout the Brain
McEwen, B. (2002) · Recent Progress in Hormone Research · doi:10.1210/rp.57.1.357 · Cited by 915
Estrogen and cognitive functioning in women
Sherwin, B. B. (2003) · Endocrine Reviews · doi:10.1210/er.2001-0016 · Cited by 560
17β-Estradiol Enhances NMDA Receptor-Mediated EPSPs and Long-Term Potentiation
Foy, M. R., Xu, J., Xie, X., Brinton, R. D., Thompson, R. F., & Berger, T. W. (1999) · Journal of Neurophysiology · doi:10.1152/jn.1999.81.2.925 · Cited by 519
Self-citation
Cited by
The 2017 hormone therapy position statement of The North American Menopause Society
(2017) · Menopause · doi:10.1097/gme.0000000000000921 · Cited by 1,001
Alzheimer’s disease: risk factors and potentially protective measures
Silva, M. V. F., Loures, C. D. M. G., Alves, L. C. V., de Souza, L. C., Borges, K. B. G., & Carvalho, M. D. G. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0524-y · Cited by 937
Gillies, G. E., & McArthur, S. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002071 · Cited by 733
Neurotrophic and neuroprotective actions of estrogen: Basic mechanisms and clinical implications
Brann, D. W., Dhandapani, K., Wakade, C., Mahesh, V. B., & Khan, M. M. (2007) · Steroids · doi:10.1016/j.steroids.2007.02.003 · Cited by 647
Estrogen: A master regulator of bioenergetic systems in the brain and body
Rettberg, J. R., Yao, J., & Brinton, R. D. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2013.08.001 · Cited by 534
Self-citation
Metadata
- Authors
- BRINTON, R. D.
- Venue
- Annals of the New York Academy of Sciences
- Publisher
- Wiley
- Published
- 2005-06
- Volume
- 1052
- Issue
- 1
- Pages
- 57-74
- ISSN
- 0077-8923 (ISSN-L)
- 1749-6632
- OpenAlex
- W2067099461
- Cited by
- 176
- References
- 3
- FWCI
- 5.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Investigative Models for Determining Hormone Therapy‐Induced Outcomes in Brain: Evidence in Support of a Healthy Cell Bias of Estrogen Action. https://app.cochat.ai/papers/10.1196/annals.1347.005
- The paper
- BRINTON, R. D. (2005). Investigative Models for Determining Hormone Therapy‐Induced Outcomes in Brain: Evidence in Support of a Healthy Cell Bias of Estrogen Action. Annals of the New York Academy of Sciences. https://doi.org/10.1196/annals.1347.005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.